These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8956310)

  • 1. Bisphosphonates prevent the hungry bone syndrome.
    Kumar A; Ralston SH
    Nephron; 1996; 74(4):729. PubMed ID: 8956310
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of parathyroid levels and bone densitometry after cinacalcet treatment in severe primary hyperparathyroidism.
    Ogrin C
    Minerva Endocrinol; 2013 Sep; 38(3):337-8. PubMed ID: 24126554
    [No Abstract]   [Full Text] [Related]  

  • 3. [Primary hyperparathyroidism in a patient with Paget's bone disease].
    Guijarro de Armas MG; Pavón de Paz I; Zubieta Tabernero J; Civantos Modino S; Montaño Martínez JM; Díaz Guardiola P
    Endocrinol Nutr; 2010 Apr; 57(4):170-3. PubMed ID: 20381437
    [No Abstract]   [Full Text] [Related]  

  • 4. Post-partum hypercalcemia in hereditary hyperphosphatasia (juvenile Paget's disease).
    Chosich N; Long F; Wong R; Topliss DJ; Stockigt JR
    J Endocrinol Invest; 1991; 14(7):591-7. PubMed ID: 1940065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure.
    Geng Z; Monier-Faugere MC; Bauss F; Malluche HH
    Clin Nephrol; 2000 Jul; 54(1):45-53. PubMed ID: 10939756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alkaline phosphatase: better than PTH as a marker of cardiovascular and bone disease?
    Lau WL; Kalantar-Zadeh K; Kovesdy CP; Mehrotra R
    Hemodial Int; 2014 Oct; 18(4):720-4. PubMed ID: 25597344
    [No Abstract]   [Full Text] [Related]  

  • 7. Controlled trial of calcitriol in hemodialysis patients.
    Baker LR; Muir JW; Sharman VL; Abrams SM; Greenwood RN; Cattell WR; Goodwin FJ; Marsh FP; Adami S; Hately W
    Clin Nephrol; 1986 Oct; 26(4):185-91. PubMed ID: 3536232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of aminohydroxypropylidene diphosphonate on the bone metabolism of patients with parathyroid adenoma.
    Ishimura E; Miki T; Koyama H; Harada K; Nakatsuka K; Inaba M; Nishizawa Y; Morii H
    Horm Metab Res; 1993 Sep; 25(9):493-7. PubMed ID: 8225204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory aids in the diagnosis of metabolic bone disease.
    Goldsmith RS
    Orthop Clin North Am; 1972 Nov; 3(3):545-60. PubMed ID: 4344932
    [No Abstract]   [Full Text] [Related]  

  • 10. [Corticotherapy and bisphosphonates].
    Cimaz R
    Arch Pediatr; 2005 Jun; 12(6):686-7. PubMed ID: 15904771
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
    Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
    J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute presentation of a giant intrathyroidal parathyroid adenoma: a case report.
    Rutledge S; Harrison M; O'Connell M; O'Dwyer T; Byrne MM
    J Med Case Rep; 2016 Oct; 10(1):286. PubMed ID: 27756436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates.
    Lazarovici TS; Mesilaty-Gross S; Vered I; Pariente C; Kanety H; Givol N; Yahalom R; Taicher S; Yarom N
    J Oral Maxillofac Surg; 2010 Sep; 68(9):2241-7. PubMed ID: 20728033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypercalcemia].
    Matikainen N
    Duodecim; 2014; 130(14):1404-12. PubMed ID: 25158579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
    Body JJ; Bartl R; Burckhardt P; Delmas PD; Diel IJ; Fleisch H; Kanis JA; Kyle RA; Mundy GR; Paterson AH; Rubens RD
    J Clin Oncol; 1998 Dec; 16(12):3890-9. PubMed ID: 9850035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hypercalcemia (with treatment)].
    Prié D
    Rev Prat; 2006 Oct; 56(16):1827-33. PubMed ID: 17315511
    [No Abstract]   [Full Text] [Related]  

  • 17. Bisphosphonate kinetics in patients undergoing continuous ambulatory peritoneal dialysis: relations to dynamic bone histomorphometry, osteocalcin and parathyroid hormone.
    Joffe P; Hyldstrup L; Heaf JG; Pødenphant J; Henriksen JH
    Am J Nephrol; 1992; 12(6):419-24. PubMed ID: 1292341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recovery of parathyroid hormone secretion during correction of tumor-associated hypercalcemia.
    Body JJ; Dumon JC; Seraj F; Cleeren A
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1385-8. PubMed ID: 1592885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates: from grandparents to grandchildren.
    Srivastava T; Alon US
    Clin Pediatr (Phila); 1999 Dec; 38(12):687-702. PubMed ID: 10618761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates and primary hyperparathyroidism.
    Rodan GA
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N150-3. PubMed ID: 12412793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.